A. Chaouat (Vandoeuvre-Les-Nancy, France), X. Jais (Clamart, France), P. Corris (Newcastle-Upon-Tyne, United Kingdom), S. Gaine (Dublin, Ireland)
Late-breaking abstract: 5-HT mediates susceptibility of rats with low intrinsic aerobic capacity to hypoxia-induced pulmonary hypertension
N. Duggan, L. Ciuclan, V. Burton, O. Bonneau, D. Rowlands, M. Hussey, J. Roger (Horsham, United Kingdom)
|  |
Spirometric corroboration of radiolographic changes suggestive of COPD and influence on ventilation-perfusion scanning
J. Abbott, S. Kinrade, A. Lakhanpal, H. Burhan (Liverpool, United Kingdom)
| |
Comparative effects of amlodipine and sildenafil on the NT-proBNP levels of patients with COPD-induced pulmonary hypertension
S. Ziaie, F. Fahimi, B. Sharif-Kashani, S. Baniasadi, A. Hamraghani, J. Salamzadeh (Tehran, Islamic Republic Of Iran)
| |
Prevalence of pulmonary hypertension and right ventricular dysfunction in patients with mixed types of ILD
C. Andersen, S. Mellemkjær, O. Hilberg, U. Simonsen, J. E. Nielsen-Kudsk, E. Bendstrup (Aarhus, Denmark)
|  |
Non-invasive evaluation in prediction of pulmonary hypertension in patients with idiopathic pulmonary fibrosis
F. Salajka, V. Bartoš, J. Novosad, J. Štásek, J. Bis, M. Brtko, P. Polanský, V. Koblízek, V. Sedlák (Hradec Králové, Czech Republic)
| |
Endothelial dysfunction in patients with chronic obstructive pulmonary disease
N. A. Kuzubova, E. Surkova, A. Y. Gichkin, O. N. Titova, M. D. Didur (Saint Petersburg, Russian Federation)
| |
The influence of right ventricular diastolic functions and pulmonary hypertension on exercise limitation and their relationship with serum NT-proBNP levels in COPD
T. Sahin Ozdemirel, B. Yetis, N. Bayraktar, S. Savas Bozbas, E. Karacaglar, G. Ulubay (Ankara, Turkey)
| |
Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension
S. Ulrich, G. Suna, L. Huber, U. Treder, R. Speich (Zurich, Switzerland)
| |
Evaluation of left ventricular function in patients with COPD – A mono centric retrospective study
S. Bhowmick, S. Ghosh (Kolkata, India)
| |
Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors
A. Stanziola, E. Carpentieri, M. D‘Alto, P. Argiento, C. Vitale, E. Romeo, M. Pitassi, A. Molino, M. Mormile, M. Sofia (Naples, Italy)
| |
Inhalation of a prostacyclin analog (iloprost) does not improve exercise capacity in COPD with disproportional pulmonary hypertension
L. Boeck, M. Tamm, D. Stolz (Basel, Switzerland)
| |
Pulmonary hypertension and exercise performance in advanced COPD
I. Lapteva, N. Porakhonko, E. Lapteva, I. Tishkova (Minsk, Belarus)
| |
Prevalence of established and exercise induced pulmonary hypertension in COPD
J. Hilde, I. Skjorten, S. Humerfelt, V. Hansteen, M. Melsom, J. Hisdal, K. Steine (Oslo, Lorenskog, Norway)
| |
Arterial blood gases during exercise in chronic obstructive pulmonary disease with and without pulmonary hypertension
I. Skjorten, J. M. Hilde, M. N. Melsom, V. Hansteen, K. Steine, S. Humerfelt (Oslo, Lorenskog, Norway)
| |
Experimental hypoxia-induced pulmonary hypertension is prevented by moderate exercise training in mice
D. Peters, C. Klöpping, K. Krüger, C. Pilat, S. Katta, M. Seimetz, H. A. Ghofrani, R. Schermuly, W. Seeger, F. Grimminger, F. Mooren, N. Weissmann (Giessen, Bad Nauheim, Germany)
| |
Biomarkers for pulmonary hypertension in interstitial lung disease
E. Bendstrup, S. Mellemkjær, O. Hilberg, J. E. Nielsen-Kudsk, U. Simonsen, C. Andersen (Aarhus, Denmark)
| |
Pulmonary hypertension in obesity-hypoventilation-syndrome
C. Kauppert, I. Dvorak, J. Gebauer, F. Kollert, F. Heinemann, M. Pfeifer, S. Budweiser (Donaustauf, Freiburg, Rosenheim, Germany)
| |
Left ventricle diastolic dysfuntion in severe COPD and exercise tolerance
M. López, M. Muñoz, R. Planas, E. Claver, M. J. Manuel, F. Manresa, J. Dorca, S. Santos (Barcelona, Spain)
| |